Long-term study of BRL-101 for transfusion-dependent beta-thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study follows patients who have already been treated with BRL-101 for transfusion-dependent beta-thalassemia. Its goal is to track long-term outcomes and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been treated with BRL-101 for transfusion-dependent beta-thalassemia.
- You or your parent/guardian can sign a consent form agreeing to be part of this long-term study.
- You are willing and able to come for follow-up visits as required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have already received BRL-101 treatment for transfusion-dependent beta-thalassemia to check their health over time. It helps doctors understand how well the treatment works in the long run.
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
This study checks on participants who previously received the experimental treatment CS-101. It aims to track their health over time to see how safe and effective the treatment is in the long run.
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
Hear when a new Thalassemia, Beta trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.